Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of three abstracts for a poster...
Source: marketscreener.com